If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary
Chimeric antigen receptor-modified T cell (CAR-T) therapy has become a critical part of the armamentarium for the treatment of relapsed/refractory hematologic malignancies. As our experience with CAR-T therapy grows and new data emerge, the identification of suitable patients has become more complex. The Community Oncologist Patient ID Roundtable, held on May 16, 2023, brought together 3 professional societies— (American Society for Transplantation and Cellular Therapy [ASTCT], Association of Community Cancer Centers [ACCC], and Association of American Cancer Institutes [AACI])—with the aim of developing a standardized framework to enable community oncology care teams to assess patients more easily for CAR T consultation, with a focus on large B cell lymphoma (LBCL).